Japan AI in Healthcare Market Size, Share, Trends, Segmentation, and Forecast, 2026–2035

Japan AI in Healthcare Market is segmented by Component (Hardware, Software Solutions, Services), by Technology (Machine Learning, Natural Language Processing, Context-Aware Computing, Computer Vision), by Application (Critical Care, Robot-Assisted Surgery, Virtual Nursing Assistants, Administrative Workflow Assistants, Fraud Detection, Cybersecurity, Dosage Error Reduction, Medical Diagnostics, Precision Medicine, Drug Discovery & Development, Remote Patient Monitoring, Wearables, Others), by End-User (Healthcare Providers, Healthcare Payers, Healthcare Companies, Patients, Others)

Last Updated: || Author: Akshay Reddy || Reviewed: Akshay Reddy || SKU: HCIT9340

Buy any syndicated report and get free complimentary customization of up to 20% of the Report and an interactive dashboard.

Report Summary
Table of Contents
List of Tables & Figures

Market Size 2035

US$19.1 billion

CAGR (2026-2035)

36.5% CAGR

Dominating Segment

By Technology

Report Pages

202

AI in Healthcare Market Size & Forecast 2035

Japan’s AI in healthcare market is estimated at US$2.11 billion in 2025 and is projected to reach US$19.1 billion by 2035, reflecting a 36.5% CAGR from 2026 to 2035.

The market includes AI-enabled hardware, software, and services used in clinical care, medical imaging, hospital operations, drug discovery, and patient monitoring. Its commercial development is shaped by Japan’s rising healthcare needs, workforce constraints, and efforts to connect fragmented medical information. People aged 65 and older accounted for 29.4% of Japan’s population in 2025, increasing pressure to sustain access and service capacity as the working-age population declines.

The shift from pilots to broader deployment depends on more than model performance. Hospitals must integrate AI with electronic health records and clinical workflows, protect sensitive patient data, define human review responsibilities, and measure operational or clinical value. Vendors that pair AI capabilities with implementation, security, interoperability, and lifecycle support are positioned to meet these requirements.

Key Highlights

  • Software solutions are the leading component segment, reflecting their role in imaging, clinical support, and hospital administration.
  • Machine learning and computer vision support image interpretation, pattern recognition, and decision-support applications.
  • Critical care, medical diagnostics, robot-assisted surgery, and administrative workflow support are key use cases.
  • Healthcare providers are a core end-user group, evaluating clinical fit, governance, and workflow impact.
  • Medical data integration and security are central to AI adoption across multiple institutions.
  • Japan’s demographic profile supports demand for tools that can help maintain care capacity amid an aging population and staff shortages.

Market Drivers and Restraints

Aging population and pressure on care capacity

Japan’s aging population increases demand for diagnostics, chronic-care management, and coordinated services. AI can help prioritize cases, support image review, automate documentation, and identify relevant patterns in clinical information. Its value depends on its fit with existing practice and on clinicians retaining responsibility for care decisions. In 2025, Japan’s population aged 65 and older reached 36.22 million, or 29.4% of the total population.

Healthcare digitalization and data integration

Japan’s healthcare digitalization agenda includes shared platforms, electronic health record information exchange, and standardized data. These foundations can improve access to structured information for clinical AI and administrative tools. The Ministry of Health, Labour and Welfare identifies data standardization, operational efficiency, and secondary use of medical information among its digital health objectives.

Privacy, safety, and implementation hurdles

AI deployment requires clear rules for data access, consent, cybersecurity, model validation, and post-deployment monitoring. Systems used in diagnosis or treatment may also need to meet medical-device requirements. Generative AI raises additional concerns about output reliability and clinical accountability. PMDA’s September 2026 consultation draft on generative-AI medical-device software is a current regulatory signal; it remains a draft under public comment.

Market Segmentation

By Component

The market covers hardware, software solutions, and services. Software solutions are the leading component, supported by demand for diagnostic and clinical applications, workflow automation, and patient management. Hardware includes computing infrastructure needed to process medical images and other clinical information. Services span implementation, integration, validation, cybersecurity, maintenance, and user support—capabilities that become essential when AI is integrated into hospital systems.

By Technology

The report covers machine learning, natural language processing, context-aware computing, and computer vision. Machine learning supports prediction and classification, while computer vision is used to analyze radiology, endoscopy, pathology, and surgical imagery. Natural language processing can help organize clinical notes and generate documentation drafts. Context-aware computing supports systems that present relevant assistance based on clinical and operational information.

By Application

Applications include critical care, robot-assisted surgery, virtual nursing assistants, administrative workflow assistants, fraud detection, cybersecurity, dosage error reduction, medical diagnostics, precision medicine, drug discovery and development, remote patient monitoring, and wearables. Critical care and medical diagnostics require close evaluation of clinical safety and human oversight. Administrative tools, including documentation assistance, can be introduced with a narrower scope, while still requiring privacy controls and clinician review.

By End User

The market is segmented into healthcare providers, healthcare payers, healthcare companies, patients, and others. Healthcare providers are central to deployment because hospitals and clinics own many clinical workflows and medical records. Healthcare companies use AI in research, drug development, and precision medicine. Payers can apply analytics to claims and care management, while patient-facing tools support remote monitoring and health services.

The source identifies the segment categories and reports software solutions as the leading component, but it does not publish numerical shares for each segment. No segment percentages are assigned here.

Japan Market Analysis

Japan’s opportunity is concentrated in systems that address care capacity while meeting requirements for safety, governance, and integration. The national digital health agenda provides a basis for connected services, but hospital adoption still depends on compatibility with existing records and information systems. The Digital Agency and the Ministry of Health, Labour and Welfare track measures such as electronic records, online prescriptions, information sharing, and personal health records through a healthcare DX dashboard.

Recent deployments illustrate different paths to adoption. Kansai Medical University and IBM Japan developed a shared medical AI platform for three affiliated hospitals. Its first application supports clinical summaries for physicians and nurses. The platform connects with the hospitals’ electronic records and includes FHIR-compatible data exchange and a zero-trust security system. The partners report that a nursing summary task that previously took around 30 minutes can be completed in five minutes with the tool, while clinical staff retains final review.

Clinical software is also progressing through Japan’s regulatory pathway. In March 2026, the National Cancer Center and Jmees announced approval of SurVis-Pel, an AI-based endoscopic surgery support program. It highlights key anatomical structures during pelvic lymph node dissection. A performance evaluation reported improved physician recognition sensitivity for the assessed structures when the product was used.

Regional Deployment Considerations

Tokyo, Osaka, and other metropolitan areas have large hospital systems, research institutions, and technology partners that can support early implementation. Regional hospitals face pressure to extend limited staffing and coordinate care across dispersed populations. Deployment models that reduce the need for each institution to build a separate AI stack may support wider adoption, provided they address data governance and local workflows.

Competitive Landscape

The market includes global technology companies, Japanese IT providers, specialist medical AI developers, and healthcare robotics companies. The report names IBM, FUJITSU, Microsoft, Cyberdyne Care Robotics, LPIXEL, Rakuten Group, MOLCURE, Medmain, and AI Medical Service among the major participants.

Competition depends on the ability to integrate AI into clinical systems and demonstrate value in real operating conditions. Vendors with hospital relationships, EHR compatibility, Japanese-language performance, and strong data-security capabilities may be better placed to scale. Specialist companies can focus on imaging, endoscopy, pathology, or surgical support, while larger technology providers compete through cloud infrastructure, data platforms, and enterprise integration.

IBM

IBM participates through healthcare IT, AI, cloud, and data integration capabilities. In Japan, IBM partnered with Kansai Medical University on a shared medical AI platform supporting documentation workflows across three hospitals. The platform links to the university’s electronic medical record environment and is designed to support additional applications across the affiliated hospitals. The deployment illustrates IBM’s position in enterprise projects where cybersecurity, interoperability, and oversight matter alongside model functionality.

FUJITSU

Fujitsu provides healthcare information systems, cloud infrastructure, and AI services for Japanese medical institutions. In May 2026, Fujitsu and IBM Japan formalized plans to develop a sovereign cloud platform for medical use, integrate data across institutions, and support the joint use of medical AI solutions. Data sovereignty and system integration are central to this collaboration. Fujitsu is also leading healthcare data platform development with SMBC Group and SoftBank, including planned AI services for healthcare institutions.

Microsoft

Microsoft supplies cloud and AI technologies used by healthcare providers, technology partners, and life-sciences companies. In Japan, its technology supports projects focused on the secure use of generative AI in hospitals. A project at JCHO Osaka Hospital with Fujitsu Japan and Fortience Consulting began in February 2026 to establish governance and apply generative AI to discharge summaries and nursing handoffs. Microsoft’s role includes cloud and AI infrastructure, while the hospital and partners define operational controls and workflows.

LPIXEL

LPIXEL is a Japanese medical imaging AI company focused on diagnostic support and image analysis. It represents specialist developers working on defined clinical tasks in collaboration with medical institutions. The company is listed among the market’s major participants. For products used in clinical decision-making, adoption depends on validation, regulatory status, workflow fit, and evidence that the software assists clinicians while preserving professional judgment.

Strategic Takeaways

  • Japan’s AI in healthcare market is calculated at US$2.11 billion in 2025 and US$19.1 billion by 2035, using the source’s stated 36.5% CAGR.
  • Software solutions lead the component categories, while integration, governance, and lifecycle services remain essential to hospital deployment.
  • Japan’s 2025 population aged 65 and older reached 36.22 million, reinforcing the need for tools that support care capacity and reduce administrative work.
  • Multi-hospital platforms can enable repeatable deployment, but shared infrastructure must protect patient privacy, security, and institutional control.
  • Clinical AI products, operational documentation tools, and research demonstrations have different adoption and regulatory requirements and should be evaluated separately.
  • PMDA’s September 2026 draft review points for generative-AI SaMD are under consultation and should not be treated as final guidance or an approval standard.
  • Procurement evaluation should track workflow time, clinician override rates, interoperability, performance across patient groups, security controls, and total implementation cost.

Recent Developments

  • PMDA opened consultation on draft review points for generative-AI medical-device software on September 18, 2026. The consultation runs through March 17, 2027. The document remains a draft and is not a product approval.
  • Japan’s Digital Agency and the Ministry of Health, Labour and Welfare updated the healthcare DX dashboard on September 30, 2026. It tracks national measures covering electronic records, prescription services, information sharing, and personal health records.
  • Kansai Medical University and IBM Japan launched a shared medical AI platform in July 2026. Its first operational application supports drafting nursing, discharge, and outpatient summaries across three affiliated hospitals, with clinical staff retaining final review.
  • The National Cancer Center Hospital launched an AI telephone system for first-visit appointments on October 1, 2026. The service applies AI to a patient-facing administrative workflow at a major cancer center.
  • Fujitsu and IBM Japan formalized their healthcare collaboration on May 15, 2026. The companies plan a sovereign cloud platform for medical use, EHR operation, cross-institution data integration, and shared medical AI services.
  • SMBC Group, Fujitsu, and SoftBank agreed to build a Japan-developed healthcare platform in May 2026. Fujitsu will lead the data platform and healthcare AI work. The partners set goals of reaching 60 million users and 4,000 medical institutions; these are targets, not achieved deployment figures.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan AI in Healthcare Market report delivers a detailed analysis with 60+ key tables, more than 50  visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Why purchase Japan AI in Healthcare Market report?

Technological Innovations

Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.

Product Performance & Market Positioning

Analyzes product performance, market positioning, and growth potential to optimize strategies.

Real-World Evidence

Integrates patient feedback and data into product development for improved outcomes.

Physician Preferences & Health System Impact

Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.

Market Updates & Industry Changes

Covers recent regulatory changes, new policies, and emerging technologies.

Competitive Strategies

Analyzes competitor strategies, market share, and emerging players.

Pricing & Market Access

Reviews pricing models, reimbursement trends, and market access strategies.

Market Entry & Expansion

Identifies optimal strategies for entering new markets and partnerships.

Regional Growth & Investment

Highlights high-growth regions and investment opportunities.

Supply Chain Optimization

Assesses supply chain risks and distribution strategies for efficient product delivery.

Sustainability & Regulatory Impact

Focuses on eco-friendly practices and evolving regulations in healthcare.

Post-market Surveillance

Uses post-market data to enhance product safety and access.

Pharmacoeconomics & Value-Based Pricing

Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

Target Audience 2026

Manufacturers

Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

Regulatory & Policy

Compliance Officers, Government, Health Economists, Market Access Specialists.

Application & Innovation

AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

Investors

Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

Consulting & Advisory

Healthcare Consultants, Industry Associations, Analysts.

Supply Chain

Distribution and Supply Chain Managers.

Consumers & Advocacy

Patients, Advocacy Groups, Insurance Companies.

Academic & Research

Academic Institutions.

Save 31% on all licenses
Single User$3175$2189Corporate$6250$4309

Free 20% customization + dashboard

Trusted by Global Leaders

ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
FAQ’s

  • By 2025 Japan’s AI in healthcare market size is US$2.11 billion, and is projected to reach US$19.1 billion by 2035.

  • Software solutions are identified as the leading component segment.

  • The report covers machine learning, natural language processing, context-aware computing, and computer vision.

  • Applications include critical care, diagnostics, surgical support, virtual nursing, administrative workflow assistance, precision medicine, drug discovery, and remote monitoring.

  • End-user categories include healthcare providers, healthcare payers, healthcare companies, patients, and others.

  • Demand is supported by an aging population, workforce constraints, healthcare digitalization, and the need to improve clinical and administrative workflows.

  • Key hurdles include data privacy, cybersecurity, EHR integration, clinical validation, regulatory requirements, and the need for human oversight.

  • PMDA reviews medical devices and software, including qualifying AI-based SaMD. In September 2026 it opened public consultation on draft review points for generative-AI medical-device software.

  • The report lists IBM, FUJITSU, Microsoft, Cyberdyne Care Robotics, LPIXEL, Rakuten Group, MOLCURE, Medmain, and AI Medical Service.
PDF
DataM
Japan AI in Healthcare Market Report
SKU: HCIT9340

Data-Backed Decisions Start Here

Explore how our research empowers industry leaders to cut through uncertainty. Get a free sample of this report or tailor it precisely to your business needs.

ISO 27001 Certified
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
Related Reports